FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1. Block
listing Interim Review
1 December 2025
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed
electronically and provided to a PIP.
(Note: Italicised terms have the same meaning as given in the
Listing Rules.)
Date: 1
December 2025
|
Name of applicant:
|
ASTRAZENECA PLC
|
|||
|
Name of scheme:
|
ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA
SAVINGS-RELATED SHARE
OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC
2012 SAVINGS-RELATED SHARE OPTION SCHEME
|
|||
|
Period of return:
|
From:
|
1 JUNE 2025
|
To:
|
30 NOVEMBER 2025
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
3,688,383
|
|||
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|||
|
Less: Number
of securities issued/allotted
under scheme(s) during period (see UKLR
20.6.7G):
|
67,907
|
|||
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
3,620,476
|
|||
|
Name of contact:
|
Hannah Tattersall
|
|
Telephone number of contact:
|
+44 (0)20 3749 5000
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 01 December 2025
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|